# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹1,983 Cr** Q3 FY26 (+3% YoY, +3% QoQ) · **₹5,820 Cr** 9M FY26 * **EBITDA:** **₹219 Cr** Q3 FY26 (+16% YoY) · **₹658 Cr** 9M FY26 (Margin: 11% vs. 10% prior) * **PAT:** **₹331 Cr** 9M FY26 · **PBT:** **₹151 Cr** Q3 FY26 (+12% YoY, incl. ₹84 Cr one-time labor provision) * **Balance Sheet:** **Net Worth:** **₹5,651 Cr** · **Finance Costs:** **₹11 Cr** Q3 · **D&A:** **₹58 Cr** Q3 ## B. Revenue Growth * **Resilient Top-Line:** Revenue growth sustained at 3% YoY and sequentially, driven by volume gains, higher plant utilization, and stable domestic demand. * **Segment Divergence:** Advanced Intermediates (AI) growth primarily price-led, not volume-driven, signaling limited underlying demand strength. * **Reporting Clarity:** Discrepancy between standalone and segment revenue/EBIT explained by inclusion of Deepak Chem Tech’s AI business within DNL’s AI segment. ## C. EBITDA & Margins * **Margin Expansion Despite Headwinds:** EBITDA margin improved to 11% on operating leverage and cost discipline, even as select products faced pricing pressure. * **Standalone Gross Margin Pressure:** Material margin in standalone business fell to **6%**, multi-year low, due to spot procurement of nitric acid and adverse U.S. duty timing. * **Phenolics Outperformance:** Segment delivered **150 bps sequential gross margin expansion** on favorable procurement and pricing differentials despite weak phenol spreads. ## D. Profitability Trends * **Mixed Profitability Signal:** Strong volume growth offset by transitional margin softness and **one-time ₹84 Cr labor-related provision**, still yielding double-digit PBT growth. * **Capital Efficiency Intact:** Consolidated ROCE held at **15%**, reflecting disciplined capital deployment and durable returns. ## E. Balance Sheet Strength * **Self-Funded Growth Trajectory:** Rising D&A (**₹58 Cr**) reflects recent commissioning of nitration/hydrogenation units, supporting future capacity absorption. * **Proactive Working Capital Management:** Ongoing optimization in inventory, supply chain, and receivables bolstering cash flow and financial flexibility. --- # 2. Segment & Product Performance ## A. Key Figures * **Phenolics Revenue:** **₹1,334 Cr** Q3 FY26 · **EBIT:** **₹145 Cr** (+20% YoY) * **Advanced Intermediates Revenue:** **₹652 Cr** Q3 FY26 (+18% YoY, +11% QoQ) · **EBIT:** **₹15 Cr** ## B. Phenolics Business * **Robust Segment Performance:** Phenolics delivered strong double-digit EBIT growth on the back of higher sales volumes, improved plant utilization, and process optimization gains. * **Demand Tailwinds:** Domestic phenol demand remains resilient, supported by India’s growth story and downstream investments, with polycarbonate import demand surging **over 50%** in recent years. * **Strategic Integration:** Second phenol plant to feed internal polycarbonate project while maintaining market supply, reinforcing vertical integration and long-term margin resilience. * **Pricing Dynamics:** Premium realization driven by **100% non-co-mingled, high-grade output** and logistical advantages—not universal over-spec—bolstering customer stickiness. ## C. Advanced Intermediates * **Volume Growth Amid Margin Pressure:** Segment achieved strong revenue growth, but EBIT remained constrained due to Chinese dumping, global oversupply, and self-inflicted pricing aggression post-commissioning. * **Strategic Recalibration Underway:** Focus shifting from volume push to **higher-margin product slate** and price optimization, supported by debottlenecked capacity and customer co-development. * **New Product Pipeline:** **~15 new products** in development across mining chemicals, flame retardants, and personal care, with **MIBC seed marketing showing positive traction** and pharmacopoeia-grade acetone now in early commercialization. ## D. Explosives & Mining * **Emerging Volume Engine:** Explosives segment gaining significant traction in India, with TNT production expanding via deep customer partnerships to meet **global military-grade standards** in mining and defence. * **Cross-Segment Demand Recovery:** Stronger demand expected in dyes, pigments, polymers, and personal care, while agrochemicals show only marginal improvement with lagged impact from market shifts. --- # 3. Capacity & Utilization ## A. Key Figures * **Total CAPEX:** ₹1,200–1,300 Cr (cumulative) * Asset Utilization: 95–105% (nitration, hydrogenation, nitric acid) from this quarter onwards ## B. Plant Commissioning * **Strategic Project Momentum:** India’s first integrated propylene-to-polycarbonate facility advancing with asset relocation from **Stade, Germany**, and on-track commissioning by **December 2027**. * **Near-Term Commissioning:** MIBK/MIBC project on track for current-quarter launch, with **phased ramp-up in Q1 FY27** due to complex, high-CAPEX technology. * **Fluorination & Nitric Acid Ramp-Up:** Nitric acid plant commissioned in **mid-Dec 2025**, now nearing full internal consumption; fluorination and diazotization assets commissioned in **May**, ramping gradually with demand. * **New Product Commercialization:** Most new products validated at pilot scale, with **staggered commercialization** expected over coming months pending customer approvals. * **Integrated Complex Development:** Accelerated investments in **Deepak Chem Tech** and a **mega integrated cumene-to-polycarbonates value chain** underscore long-term capacity scaling. ## C. Asset Utilization * **Peak Output Achieved:** Phenolics production surpassed prior peaks, reaching full **350,000 MT winter capacity**, supporting margin expansion through reduced inefficiencies. * **Near-Full Utilization:** Nitration, hydrogenation, and nitric acid assets operating at **95–105% utilization**, reflecting strong operational execution and demand alignment. ## D. Debottlenecking Progress * **Ongoing Optimization:** Active debottlenecking initiatives across **phenol, nitric acid, and nitration assets**, synchronized with maintenance cycles and future capacity planning. * **Growth Optionality:** Management remains confident in identifying **new debottlenecking opportunities** despite volatile phenol and acetone markets. --- # 4. Export & Geography Mix ## A. Key Figures * **Domestic Revenue:** **₹1,647 Cr** Q3 FY26 · **₹4,903 Cr** 9M FY26 * **Export Revenue:** **₹328 Cr** Q3 FY26 · **₹864 Cr** 9M FY26 * **Domestic:Export Mix:** **83:17** in Q3 FY26 ## B. Domestic vs Export * **Stable Geographic Mix:** Domestic dominance maintained at 83% despite active global expansion, underscoring resilient local demand and steady international uptake. * **Margin Pressure:** Aggressive supply ramp-up in domestic and near-domestic markets weighed on contribution margins due to elevated input costs. ## C. EU & U.S. Markets --- # 5. Input Cost & Integration ## A. Key Figures * **Nitric Acid Self-Sufficiency:** **~100%** of requirement now self-manufactured * **Renewable Energy Mix:** **60–70%** of Group’s energy from hybrid renewable sources ## B. Nitric Acid Integration * **Full Vertical Integration Achieved:** Deepak Group is now likely the only fully integrated aromatic-to-amine player, enhancing raw material security and structural margin stability. * **Profitability Inflection Expected:** Green shoots in Q4 FY26 anticipated from full integration of nitric acid, nitration, and hydrogenation capacities, enabling cost-efficient operations and stronger margins in Advanced Materials and standalone segments. * **Near-Term Margin Pressure Absorbed:** Q3 FY26 margin compression stemmed from technical delays and strategic procurement of nitric acid at elevated spot rates, disrupting planned integration sequencing. * **Long-Term EBITDA Leverage:** Upstream investments like nitric acid production do not generate direct revenue but are expected to drive substantial EBITDA improvement in the AI business. ## C. Raw Material Sourcing * **Cost Advantage from Trade Policy:** Potential for improved cost efficiency through duty-free or reduced-duty imports of key raw materials like cyanuric chloride from Europe under FTA provisions. * **External Sourcing Headwinds:** Despite robust sales volumes, margin pressure persisted due to unplanned external procurement of raw materials at higher costs, deviating from integrated production plans. --- # 6. Risks & Trade Factors ## A. Key Figures * **Sodium Nitrite Export Tariff Gap:** Reduced from **~106%** to significantly lower levels, with ADD now **0%** and reciprocal duty down to **18%** * **Historical U.S. Export Volume:** ~**5,000 tonnes/year** prior to tariff imposition * **Tariff Overhang Duration:** **8 months** of elevated tariffs (>105%) recently resolved * **B. S. Government Shutdown Delay:** **45–48 days**, delaying antidumping ruling announcement ## B. Chinese Overcapacity * **Global Pressure Persists:** Aggressive Chinese pricing and expanding phenol capacity create headwinds, though Indian markets remain largely insulated due to regional cost advantages and trade dynamics. * **Shifting Production Landscape:** Permanent shutdowns in Singapore and Far East contrast with new Chinese builds, signaling structural realignment in global supply chains. * **Limited Dumping Risk:** Despite European producers' struggles, **no significant phenol dumping into India** is expected due to competitive Asian supply and minimal import duty impact. * **Policy Uncertainty Ahead:** Chinese deflation measures and the upcoming **15th Five-Year Plan** will determine actual policy execution; current signals remain intent-based. * **Selective Pricing Upside:** Potential for **price improvements** in Deepak’s product basket if Chinese VAT rebates are not renewed or anti-dumping actions take effect. ## C. Tariff & Duty Shifts * **Major Trade Relief Achieved:** Removal of **antidumping duty on sodium nitrite exports to the U.S.** and sharp reduction in reciprocal tariffs unlock recovery of lost volumes and margins. * **Favorable Policy Tailwinds:** U.S.-India tariff shifts, potential bilateral deals, and the **India-EU trade agreement** enhance access to high-value markets and global supply chains. * **Export Recovery Opportunity:** With the **~106% price gap now narrowed**, company is well-positioned to regain U.S. market share, supported by historical customer relationships. * **Operational Disruption from Delay:** The **45–48 day U.S. government shutdown** delayed communication of a favorable ruling, disrupting sales cycles and planning. * **Customer Destocking Impact:** Temporary demand softness in U.S. and Europe due to year-end inventory rationalization amid prior tariff concerns. --- # 7. Guidance & Outlook ## A. Q4 FY26 Recovery * **Cautious Q4 Improvement Expected:** Performance is anticipated to improve sequentially in Q4 FY26, with momentum building from mid-quarter, though outlook remains tempered by **Chinese overcapacity**. * **Resolved External Headwinds:** Supply chain and regulatory delays—nitric acid supply and antidumping duty—have been cleared, removing prior constraints. * **Favorable Phenolics Trends:** Post-Q3 price recovery and widening India-specific spreads signal strong segment tailwinds for Q4. * **Seasonal & Structural Volatility:** Q4 is inherently unpredictable due to China's New Year, India's financial year-end, and government CAPEX cycles affecting demand patterns. * **Near-Term Partnership Upside:** Benefits from strategic collaborations expected within **3–6 months**, driven by customer-side investments, not Deepak’s capital outlay. ## B. FY27 Ramp-up Plan * **Strategic Focus on Diversification:** Growth to be driven by new capacity ramp-up, specialty product expansion, and geographic reach, underpinned by financial discipline. * **Polycarbonate Project on Track:** Funding arrangements are in final stages, ensuring balance sheet readiness and paving way for **revenue diversification and margin expansion**. * **New Asset Utilization to Lift Output:** Photochemical, chlorination, and fluorination units expected to see improved utilization starting **Q1 FY27**. * **BTC-to-BTF Transition in Q1 FY27:** Production shift enables **multiproduct flexibility** on shared lines, enhancing operational efficiency. * **MIBK/MIBC/Nitro Aromatics to Debut in Q1 FY27:** Revenue contribution expected post-commissioning, despite current import dependency and oversupply challenges.